Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ClpP CRISPR/Cas9 KO Plasmid (m): sc-424769
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ClpP CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ClpP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ClpP Antibody (B-12): sc-271284
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ClpP CRISPR/Cas9 KO Plasmid (m) | sc-424769 | 20 µg | $397.00 |
Overview
Clpp encodes the mitochondrial ATP-dependent caseinolytic peptidase proteolytic subunit ClpP, a serine protease that partners with the ClpX unfoldase to remove damaged or misfolded proteins and maintain proteostasis within the matrix. This quality-control axis supports oxidative phosphorylation capacity, limits proteotoxic and oxidative stress, and influences mitochondrial unfolded protein response signaling. ClpP activity connects to pathways governing energy metabolism, mitochondrial biogenesis, and stress-adaptive transcriptional programs. Dysregulated CLPP function has been linked to mitochondrial dysfunction phenotypes and is commonly interrogated in models of neurodegeneration, metabolic disease, and cancer-associated mitochondrial rewiring.
ClpP CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Clpp gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Clpp together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Clpp open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ClpP protein expression.
This CRISPR knockout system enables efficient generation of Clpp-deficient cell models for investigation of ClpP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Clpp exon(s) critical for ClpP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Clpp genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ClpP CRISPR/Cas9 KO Plasmid (m) and ClpP CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Clpp locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ClpP HDR Plasmid (m) and ClpP HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Clpp homology arms to support homology-directed repair at defined Clpp target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.